Results 61 to 70 of about 37,133 (255)

Can mutation abundance assess the biological behavior of BRAF V600E-positive papillary thyroid carcinoma?

Journal of Translational Medicine
Background BRAF V600E mutation is the most common genetic change in papillary thyroid carcinoma (PTC). Nevertheless, the association between BRAF V600E mutation status and abundance and the biological behavior of PTC is unclear.
Yeqin Ni, Ping Song, Xiangfeng Lin, Jingjing Shi, Qian Shi, Yuanhui Li, Siyu Zhu, Tianhan Zhou, Yanping Xun, Shirong Zhang, Xingchang Ren, Kaining Lu, Fan Wu, Wei Wang, Pan Zhao, Rongjing Zhou, Wenhua Zhang, Dandan Li, Jiaoping Zhang, Chuanghua Chen, Linlin Mao, Li Zhou, Gang Pan, You Peng, Yunxian Yu, Yuying Chen, Rong Ni, Guhan Luo, Yu Zhang, Jugao Fang, Haitao Zheng, Dingcun Luo   +31 more
doaj   +1 more source

BRAF wild-type melanoma in situ arising in a BRAF V600E mutant dysplastic nevus [PDF]

, 2015
IMPORTANCE The BRAF V600E mutation accounts for the majority of BRAF mutations found in cutaneous melanoma and is also commonly found in nevi. We used dermoscopy-targeted sampling and a microbiopsy device coupled with DNA sequence analysis to highlight ...
Flewell-Smith, Ross, Jagirdar, Kasturee, Lambie, Duncan, Lin, Lynlee L., Prow, Tari W., Schaider, Helmut, Soyer, H. Peter, Sturm, Richard A., Tan, Jean-Marie   +8 more
core   +1 more source

A BRAF V600E Mutation in RET‐Negative Medullary Thyroid Cancer [PDF]

Case Reports in Endocrinology, 2020
We report the case of a woman with a sporadic medullary thyroid carcinoma. Genomic analysis found that her tumor did not contain any common RET mutations but did harbor a BRAF V600E mutation.
Richard J. Robbins, Jessica S. Thomas, Patricia Mejia Osuna, Jawairia Shakil   +3 more
openaire   +3 more sources

Strawberry Notch 1 Acts as a Transcriptional Regulator Driving Oncogenic Programs in Liver Carcinogenesis

Advanced Science, EarlyView.
This study reports that SBNO1 protein is upregulated in several cancer entities. SBNO1 protein interacts with the basal transcription factor TFIID via TAF4, enabling its recruitment to transcription start sites and the modulation of target gene expression.
Sarah Fritzsche, Raisatun Nisa Sugiyanto, Kira Gür, Alina Krumme, Maxime Le Marois, Angelika Fraas, Aslihan Inal, Mario Huerta, Vanessa Henriques, Eva Eiteneuer, Thomas Albrecht, Alphonse Charbel, Michael T. Dill, Carsten Sticht, Carolina De La Torre, Stefan Pusch, Arianeb Mehrabi, Kai Breuhahn, Junfang Ji, Peter Schirmacher, Benjamin Goeppert, Stephanie Roessler   +21 more
wiley   +1 more source

Molecular Pattern and Clinical Implications of KRAS/NRAS and BRAF Mutations in Colorectal Cancer

Current Issues in Molecular Biology, 2023
The aim of our study was to evaluate the incidence of KRAS/NRAS and BRAF mutations, analyze molecular patterns, and investigate associations with clinical parameters of these mutations in CRC KRAS/NRAS and BRAF mutations analyzed by next-generation ...
İvo Gökmen, Ebru Taştekin, Nazan Demir, Erkan Özcan, Fahri Akgül, Muhammed Bekir Hacıoğlu, Bülent Erdoğan, Sernaz Topaloğlu, İrfan Çiçin   +8 more
doaj   +1 more source

Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next‐Generation Approaches

Advanced Science, EarlyView.
This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey, Sudhir Kumar Rai, Li Ma, Lauren Higa, Vedbar Khadka, Hua Yang, Youping Deng   +6 more
wiley   +1 more source

Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience

Therapeutic Advances in Respiratory Disease, 2018
Mutations in the BRAF oncogene are found in 2–4% of all non-small cell lung cancer (NSCLC) patients. The most common activating mutation present within the BRAF oncogene is associated with valine substitution for glutamate at position 600 (V600E) within ...
Arjun Khunger, Monica Khunger, Vamsidhar Velcheti   +2 more
doaj   +1 more source

Evaluation of the expression levels of BRAF V600E mRNA in primary tumors of thyroid cancer using an ultrasensitive mutation assay

BMC Cancer, 2020
Background The BRAF V600E gene encodes for the mutant BRAFV600E protein, which triggers downstream oncogenic signaling in thyroid cancer. Since most currently available methods have focused on detecting BRAF V600E mutations in tumor DNA, there is limited
Tien Viet Tran, Kien Xuan Dang, Quynh Huong Pham, Ung Dinh Nguyen, Nhung Thi Trang Trinh, Luong Van Hoang, Son Anh Ho, Ba Van Nguyen, Duc Trong Nguyen, Dung Tuan Trinh, Dung Ngoc Tran, Arto Orpana, Ulf-Håkan Stenman, Jakob Stenman, Tho Huu Ho   +14 more
doaj   +1 more source

BRAFV600E mutation positive metastatic melanoma in a young woman treated with anti-BRAF/anti MEK combination: a case report [PDF]

, 2015
The recent Combi-v [1] and Combi-d [2,3], phase III randomized trials, showed, respectively, an OS benefit with Dabrafenib/Trametinib combination versus Vemurafenib and an improvement in PFS and ORR with the same combination versus Dabrafenib alone ...
CORTESI, Enrico, GIOVANNONI, SARA, Giuliana, Caprio, MEZI, Silvia, MODICA, DANIELA, URBANO, FEDERICA, VERKHOVSKAIA, SOFIA   +6 more
core   +2 more sources

Dual Aptamers‐Based SETDB1 PROTACs as Effective Anti‐Tumor Strategies for Breast Cancer

Advanced Science, EarlyView.
This study establishes dual‐aptamer PROTACs targeting SETDB1 using a SETDB1‐specific aptamer conjugated to AS1411. The designed PROTACs penetrate cells, recruit MDM2 to degrade SETDB1, and inhibit cancer cell proliferation and migration. Remarkably, they also overcome tamoxifen resistance and enhance CD8+ T cell cytotoxicity, suppressing tumor growth ...
Yanxuan Guo, Yingge Lv, Shuyu Huang, Chang Liu, Yan Ouyang, Bei Lan, Chenghao Xuan   +6 more
wiley   +1 more source